Do you want to read an article? Please log in or register.
Identification of stage I/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model
Skin Cancer
Related content
Lung, Respiratory and Thoracic Cancer
Association of Survival With Adjuvant Chemotherapy Among Patients With Early-Stage Non-Small Cell Lung Cancer With vs Without High-Risk Clinicopathologic Features
JAMA Oncol.
Pathak R, Goldberg SB, Canavan M, Herrin J, Hoag JR, Salazar MC, Papageorge M, Ermer T, Boffa DJ
doi: 10.1001/jamaoncol.2020.4232.
Skin Cancer
Circulating tumor DNA predicts survival in patients with resected high risk stage II/III melanoma
Ann Oncol.
Lee RJ, Gremel G, Marshall A, Myers KA, Fisher N, Dunn J, Dhomen N, Corrie PG, Middleton MR, Lorigan P, Marais R
doi: 10.1093/annonc/mdx717.
Skin Cancer
Clinical validation of a prognostic 11-gene expression profiling score in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma
Eur J Cancer.
Amaral TMS, Hoffmann MC, Sinnberg T, Niessner H, Sülberg H, Eigentler TK, Garbe C
doi: 10.1016/j.ejca.2019.10.027.
Skin Cancer
Performance of Gene Expression Profile Tests for Prognosis in Patients With Localized Cutaneous Melanoma: A Systematic Review and Meta-analysis
JAMA Dermatol.
Marchetti MA, Coit DG, Dusza SW, Yu A, McLean L, Hu Y, Nanda JK, Matsoukas K, Mancebo SE, Bartlett EK
doi: 10.1001/jamadermatol.
RECOMMENDED
Skin Cancer
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial
Lancet Oncol.
Schadendorf D, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Lesimple T, Plummer R, Schachter J, Dasgupta K, Manson S, Koruth R, Mookerjee B, Kefford R, Dummer R, Kirkwood JM,
Long GV
doi: 10.1016/S1470-2045(18)30940-9.
Skin Cancer
Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial
J Clin Oncol.
Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, van Akkooi ACJ, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suciu S, Robert C
doi: 10.1200/JCO.20.02110.
RECOMMENDED
Lymphoma
Relapse After Early-Stage, Favorable Hodgkin Lymphoma: Disease Characteristics and Outcomes With Conventional or High-Dose Chemotherapy
★ 3
Recommended by
Alexander Meisel, Faculty Member
J Clin Oncol.
Bröckelmann PJ, Müller H, Guhl T, Behringer K, Fuchs M, Moccia AA, Rank A, Soekler M, Vieler T, Pabst T, Baues C, von Tresckow B, Borchmann P, Engert A
doi: 10.1200/JCO.20.00947.Visit the original publication at ncbi.nlm.nih.gov
Breast Cancer
Patient-centered simulations to assess the usefulness of the 70-gene signature for adjuvant chemotherapy administration in early-stage breast cancer
Breast Cancer Res Treat.
Caruana E, Foucher Y, Tessier P, Frenel JS, Classe JM,
Dantan E
doi: 10.1007/s10549-018-05107-6.
Skin Cancer
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial
doi: 10.1016/S1470-2045(20)30062-0.